Skip to content
Peptide research

VIP

Also known as Vasoactive Intestinal Peptide
Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A naturally occurring peptide marketed for anti-inflammatory, lung, and gut effects. Human evidence is moderate for its anti-inflammatory and lung-relaxing effects, but the neuroprotective, sleep, and gut benefits rest on animal and mechanism data. It sharply lowers blood pressure, clears within minutes, and carries a theoretical tumor-promotion concern, with scant long-term safety data. Not FDA-approved; sold as an unregulated research-grade product.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Potent anti-inflammatory and immunomodulatory effects

    Medium

    Reduced inflammatory markers in a small human trial; extensive supporting animal data.

  • Pulmonary vasodilation and treatment of pulmonary arterial hypertension

    Medium

    Inhaled VIP acutely lowers pulmonary vascular resistance in small human trials; long-term benefit unproven.

  • Neuroprotection against neurodegenerative disease

    Low

    Protects neurons in animal models via a clear mechanism; no human trials conducted.

Evidence limits

Evidence Level
Moderate

VIP's clinical evidence base is paradoxically both extensive and incomplete. Preclinical evidence is among the strongest for any neuropeptide, with rigorous studies in Nature Medicine, JCI, Blood, and PNAS demonstrating potent immunomodulatory, neuroprotective, vasodilatory, and circadian regulatory effects. However, clinical translation has been limited. The pulmonary hypertension studies by Petkov et al. (2003) and Leuchte et al. (2008) showed clear benefits of inhaled VIP but remained small in scale. The COVID-19 ARDS trials yielded mixed results: Youssef et al. (2022, n=196) showed significant survival improvement, while the larger TESICO trial (2023; 471 randomized in the aviptadil comparison, 461 analyzed) was negative. The largest clinical experience comes from the Shoemaker CIRS protocol (10,000+ patients since 2008 using VIP nasal spray), which reports beneficial outcomes for biotoxin illness and chronic inflammation, but this evidence is observational and has not been validated through RCTs. Major gaps include the absence of large RCTs for autoimmune indications despite exceptional preclinical results, the absence of human neuroprotection trials and of randomized trials for the CIRS indication, and the short plasma half-life (~2 minutes IV), which presents formulation challenges for clinical development.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Severe hypotension

    High

    VIP is a potent vasodilator. Can cause dangerous blood pressure drops.

  • Diarrhea-predominant IBS

    Moderate

    VIP increases intestinal secretion and motility, potentially worsening diarrhea.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Hypotension and cardiovascular effects

    High
  • Very short plasma half-life (~2 minutes IV)

    High
  • Gastrointestinal side effects

    Moderate
  • Limited long-term safety data from controlled trials

    High
  • Potential tumor-promoting effects in certain cancers

    Theoretical
  • Pregnancy and lactation safety unknown

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.